A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDle study)

HIV Clinical Trials

Volumn 7, Issue 4, 2006, Pages 155-162

  López, Juan Carlos ^a   Moreno, Santiago ^b   Jiménez Oñate, Fernando ^c   Clotet, Bonaventura ^d   Rubio, Rafael ^e   Hernández Quero, Jose ^f  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Adherence; Antiretroviral treatment; Didanosine; Virological failure

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DIET RESTRICTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAPSULES; CLINICAL TRIALS; COHORT STUDIES; DIDANOSINE; FASTING; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HIV; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TREATMENT FAILURE; VIRAL LOAD;

EID: 33750893346     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0704-155     Document Type: Article

References (19)

1. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-361.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intem Med. 2000;133:21-30.
3. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 2):S171-176.
4. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28:124-131.
5. Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs. 1999;58:1099-1135.
6. Damle BD, Kaul S, Behr D, Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol. 2002;42:791-797.
7. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002;42:419-427.
8. Iribarren JA, Labarga P, Rubio R, et al. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin. 2004;22:564-642.
9. Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Dispos. 2002;23:59-66.
10. Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother. 2002;46:385-391.
11. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:437-443.
12. Ruhnke M, Bauer FE, Seifert M, Trautmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1993;37:2153-2158.
13. Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol. 1991;40:305-308.
14. Nazareno LA, Holazo AA, Limjuco R, et al. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res. 1995;12:1462-1465.
15. Ahluwalia G, Cooney DA, Hartman NR, et al. Anomalous accumulation and decay of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metab Dispos. 1993;21:369-376.
16. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses. 2000;16:415-421.
17. la Porte C, Verweij-van Wisen C, van Ewijk N, et al. Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunters. J Clin Pharmacol. 2005;45:211-218.
18. Reynes J, Denisi R, Massip P, Izopet J, Pellegrin I, Segondy M. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group. J Acquir Immune Defic Syndr. 1999;22:103-105.
19. Maggiolo F, Migilorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther. 2001;6:249-253.